Compare Amphastar Pharmaceuticals Inc (AMPH) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Under Armour Inc Class A — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Under Armour Inc Class A trades at $5.39 (market cap $2.57B). The key difference: Under Armour Inc Class A is far larger — about 3× Amphastar Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| AMPH | UAA | |
|---|---|---|
Market Cap | $863.95M | $2.57B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $8.14 |
52-Week Low | $16.87 | $4.17 |
Enterprise Value | $1.26B | $3.55B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Under Armour (UAA) trades at $6.11, down 4.38% today, reflecting ongoing challenges. The stock shows a bearish technical trend with key support at $6. Recent Q2 2026 earnings beat expectations with EPS of $0.05 versus $0.02, but revenue declined year-over-year. Financials reveal negative net income margin of -9.98% and weak cash flow, with net cash outflow of $361.87 million in 2025. Analysts maintain a cautious stance amid soft demand in key markets.
The outlook remains challenging due to persistent revenue declines and profitability issues. Investment opportunities hinge on successful execution of turnaround strategies, but risks include intense competition and macroeconomic pressures. With a consensus price target of $5.96 below the current price, Wall Street sentiment is neutral to bearish, emphasizing the need for improved fundamentals to drive recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
